Lead Plaintiff Deadline: June 21, 2021
Please Upload related files below
Fill in below.
Looking for more?
(i) the materials submitted in support of the pimavanserin supplemental new drug application (sDNA) contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the Food and Drug Administration Agency was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
In order to be included in the lawsuit, you must have incurred a loss on shares of Acadia, either: A) purchased or acquired during the class period listed above, if applicable; or B) pursuant to the Initial Public Offering (IPO) of Acadia, if applicable.
If you suffered a loss in Acadia during the relevant time frame, or pursuant to Acadia’s IPO if listed above, you have until June 21, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.